Effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma by UPLC-MS/MS

Yang, Jinzhao; Liu, Huamin; Cai, Yuan; Wu, Yazhen; Xu, Xiaoxin; Wang, Xianqin; Lin, Chongliang

doi:10.1556/1326.2020.00761

Artykuł - szczegóły

Tytuł artykułu

Effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma by UPLC-MS/MS

Autorzy

Yang Jinzhao , Liu Huamin , Cai Yuan , Wu Yazhen , Xu Xiaoxin , Wang Xianqin , Lin Chongliang

Wybrane pełne teksty z tego czasopisma

Identyfikatory

DOI

10.1556/1326.2020.00761

Warianty tytułu

Języki publikacji

Abstrakty

Twelve Sprague-Dawley rats were randomly divided into two groups: Citrus suavissima Hort. ex Tanaka group and control group (n 5 6). The rats in Citrus suavissima Hort. ex Tanaka group were given Citrus suavissima Hort. ex Tanaka juices (1 mL/100 g) by oral administration each day, continued for 14 days; the rats in control group were given Stroke-physiological saline solution (1 mL/100 g) by oral administration each day, continued for 14 days. The rats of these two groups were given a single oral administration of erlotinib (20 mg/kg) on the 15th day. After blood sampling at different time points and processing, the concentrations of erlotinib in rat plasma were determined by the established ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. Chromatographic separation was achieved using a UPLC BEH C18 column (2.1 mm 3 50 mm, 1.7 mm) with erlotinib-d6 as an internal standard (IS). The initial mobile phase consisted of acetonitrile and water (containing 0.1% formic acid) with gradient elution. Multiple reaction monitoring (MRM) modes were utilized to conduct quantitative analysis. The sensitive, rapid and selective UPLC-MS/MS method was successfully applied to analyse the effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma. There were no significant differences in AUC(0t), t1/2, Tmax, CL, Cmax between the two groups (P > 0.05). While MRT(0t) was decreased (P < 0.05) in Citrus suavissima Hort. ex Tanaka group, compared to the control group. It showed that Citrus suavissima Hort. ex Tanaka could not affect the metabolism of erlotinib.

Słowa kluczowe

erlotinib pharmacokinetic interaction UPLC-MS/MS

Wydawca

University of Silesia in Katowice
Akademiai Kiado

Czasopismo

Acta Chromatographica

Rocznik

2021

Tom

Vol. 33, no. 1

Strony

73--77

Opis fizyczny

Bibliogr. 36 poz., rys., tab.

Twórcy

autor

Yang Jinzhao

Department of Pharmacy, Wenzhou People's Hospital, Wenzhou, 325000, PR China

autor

Liu Huamin

Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, PR China

autor

Cai Yuan

Department of Pharmacy, Wenzhou People's Hospital, Wenzhou, 325000, PR China

autor

Wu Yazhen

Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, PR China

autor

Xu Xiaoxin

Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, PR China

autor

Wang Xianqin

lankywang@163.com

Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, PR China

https://orcid.org/0000-0002-9821-3770

autor

Lin Chongliang

lcL3@wzhospital.cn

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, PR China

Bibliografia

1. Chang, L. L.; Jia, S.; Fu, Y. Y.; Zhou, T. Y.; Cao, J.; He, Q. J.; Yang, B.; Li, X.; Sun, C. D.; Su, D.; Zhu, H.; Chen, K. S. Chin. Med. 2015, 10.
2. Zhang, J. K.; Wu, Y. P.; Zhao, X. Y.; Luo, F. L.; Li, X.; Zhu, H.; Sun, C. D.; Chen, K. S. J. Funct. Foods 2014, 10, 511–9.
3. Zhang, J. K.; Zhu, X. Y.; Luo, F. L.; Sun, C. D.; Huang, J. Z.; Li, X.; Chen, K. S. J. Separ. Sci. 2012, 35, 128–36.
4. Zhu, X. Y.; Luo, F. L.; Zheng, Y. X.; Zhang, J. K.; Huang, J. Z.; Sun, C. D.; Li, X.; Chen, K. S. Int. J. Mol. Sci. 2013, 14, 8684–97.
5. Gao, W. X.; L.X.; Yu, M.; Ye, X. X.; Zhang, A. J. J. Wenzhou Univ. Nat. Sci. 2010, 31, 11–5.
6. Hu, Z. Y.; Zhang, M.; Wen, Q. G.; Wei, J.; Yi, H. L.; Deng, X. X.; Xu, X. H. J. Am. Soc. Hortic. Sci. 2007, 132, 777–82.
7. Zhang, J.; Wu, Y.; Zhao, X.; Luo, F.; Li, X.; Zhu, H.; Sun, C.; Chen, K. J. Funct. Foods 2014, 10, 511–9.
8. Zhu, X.; Luo, F.; Zheng, Y.; Zhang, J.; Huang, J.; Sun, C.; Li, X.; Chen, K. Int. J. Mol. Sci. 2013, 14, 8684–97.
9. Li, Y.-X.; Chen, X.-T.; Liu, H.-L.; Yuan, K. Asian J. Chem. 2012, 24, 53–7.
10. Chen, X.; Yuan, K.; Liu, H. J. Food Agric. Environ. 2010, 8, 150–5.
11. Chen, X.; Yuan, K.; Si, J. Int. J. Food. Sci. Nutr. 2009, 60, 116–27.
12. Hu, Z.; Zhang, M.; Wen, Q., Wei, J.; Yi, H.; Deng, X.; Xu, X. J. Am. Soc. Hortic. Sci. 2007, 132, 777–82.
13. Nian, S. Y.; Wu, Q.; Zhang, Q. W.; Lin, Y. Y.; Yang, S. P., Wu, Y. N.; Wen, C. C.; Wang, G. P.; Lin, C. L. Lat. Am. J. Pharm. 2015, 34, 1468–72.
14. Wang, Z. Y.; Zhang, Q. W.; Zhang, M. L.; Wu, H. Y.; Zhang, Y. Lat. Am. J. Pharm. 2015, 34, 313–8.
15. Zheng, Y. C.; Wang, Y. L.; Zhang, L. K.; Zhang, Q. W.; Yang, X. Z.; Lin, G. Y. Lat. Am. J. Pharm. 2014, 33, 1225–8.
16. Lin, C. L.; Chen, M. C.; Zhang, X. Q.; Wen, C. C.; Zhang, Q. W.; Cai, J. Z. Lat. Am. J. Pharm. 2013, 32, 1298–303.
17. Ding, X. T.; Zhang, C. X.; Xu, Z. S.; Zhang, Q. W.; Wu, H. Y.; Wang, Z. Y.; Ma, J. S. Lat. Am. J. Pharm. 2012, 31, 501–6.
18. Chen, L.; You, W.; Chen, D.; Cai, Y.; Wang, X.; Wen, C.; Wu, B. Biomed. Res. Int. 2018, 2018, 6562309.
19. Wang, S.; Wu, H.; Geng, P.; Lin, Y.; Liu, Z.; Zhang, L.; Ma, J., Zhou, Y.; Wang, X.; Wen, C. Biomed. Chromatogr. 2016, 30, 1145–9.
20. Wang, J. Z.; Zhou, Y. F.; Wang, C.; Chen, J. M. Lat. Am. J. Pharm. 2015, 34, 1576–84.
21. Hayashi, H., Kita, Y.; Iihara, H.; Yanase, K.; Ohno, Y.; Hirose, C.; Yamada, M.; Todoroki, K.; Kitaichi, K.; Minatoguchi, S.; Itoh, Y.; Sugiyama, T. Biomed. Chromatogr. 2016, 30, 1150–4.
22. Ma, J.; Wang, S.; Huang, X.; Geng, P.; Wen, C.; Zhou, Y.; Yu, L.; Wang, X. J. Pharm. Biomed. Anal. 2015, 111, 131–7.
23. Zhang, Q.; Wen, C.; Xiang, Z.; Ma, J.; Wang, X. J. Pharmaceut. Biomed. Anal. 2014, 90, 134–8.
24. Luo, Y.; Li, L. Y.; Cai, J. Z.; Ma, J. S.; Liu, L.; Wang, X. Q.; Jin, C. Acta Chromatogr. 2019, 31, 211–5.
25. Han, A. X.; Lin, G. Y.; Cai, J. Z.; Wu, Q.; Geng, P. W.; Ma, J. S.; Wang, X. Q.; Lin, C. L. Acta Chromatogr. 2019, 31, 99–104.
26. Yang, J. Z.; Zhong, Y. Y.; You, W. W.; Chen, D. W.; Cai, Y.; Zhou, Y. F. Lat. Am. J. Pharm. 2019, 38, 1547–51.
27. Song, H. C.; Huang, Y. W.; Zhu, D. Q.; Tong, S. H.; Zhang, M. L.; Wang, X. Q.; Bao, X. Curr. Pharmaceut. Anal. 2019, 15, 194–9.
28. Ye, W.; Lin, C.; Lin, G.; Chen, R.; Sun, W.; Wang, S.; Wang, X.; Zhou, Y. Curr. Pharmaceut. Anal. 2019, 15, 604–11.
29. Song, X.; Ju, Y.; Zhao, H.; Qiu, W. Int. J. Clin. Pharmacol. Ther. 2019, 57, 101–9.
30. Raish, M.; Ahmad, A.; Ansari, M. A.; Alkharfy, K. M.; Ahad, A.; Khan, A.; Aljenobi, F. I.; Ali, N.; Al-Mohizea, A. M. J. Food Drug Anal. 2019, 27, 332–8.
31. Radwan, A.; Sweileh, A.; Shraim, W.; Hroub, A.; Elaraj, J.; Shraim, N. Int. J. Clin. Pharm. 2018, 40, 668–75.
32. Hermann, R.; Derendorf, H.; von Richter, O.; Rostami-Hodjegan, A. J. Clin. Pharmacol. 2018, 58, 704–16.
33. Lin, G. Y.; Ma, J. S.; Xu, R. A.; Hu, L. F.; Wang, Z.; Wang, X. Q. Pharmazie 2012, 67, 242–6.
34. Calvert, H.; Twelves, C.; Ranson, M.; Plummer, R.; Fettner, S.; Pantze, M.; Ling, J.; Hamilton, M.; Lum, B. L.; RakhitA. Anticancer. Drugs. 2014, 25, 832–40.
35. Dong, P. P.; Fang, Z. Z.; Zhang, Y. Y.; Ge, G. B.; Mao, Y. X.; Zhu, L. L.; Qu, Y. Q.; Li, W.; Wang, L. M.; Liu, C. X.; Yang, L. Acta. Pharmacol. Sin. 2011, 32, 399–407.
36. Ma, J.; Wang, S.; Zhang, M.; Zhang, Q.; Zhou, Y.; Lin, C.; Lin, G.; Wang, X. Biomed. Chromatogr. 2015, 29, 1203–12.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-d5804841-2be8-4592-b4f2-87c2e4c223db